CompletedNCT05278156

Efficacy, Safety and Pharmacokinetics Study of CPL500036 (PDE10A Inhibitor) in Patients With Schizophrenia

Medication studyAges 18–65Multiple countries

The study in practice

Understand this study

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations: Budapest, Hungary · Győr, Hungary and 11 more locationsSee all locations and recruitment
Activities: Medication described in the protocol · Placebo comparator
Compensation: Payment and expense reimbursement have not been verified.

Study clarity

Study start dateStarted: May 19, 2021

Recruitment status: Completed
Enrollment listed in the registry: 189
Sponsor: Celon Pharma SA
Sponsor type: Pharmaceutical company
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 2
Locations: Hungary, Poland, Ukraine
Age range: From 18 Years to 65 Years
Official registry ID: NCT05278156
Official title: Show the full official title
Phase II, Double Blind, Randomized, Placebo Controlled, Parallel Group, Trial to Explore Efficacy, Safety and Pharmacokinetics of CPL500036 (PDE10A Inhibitor) in Patients With an Acute Exacerbation of Schizophrenia

Completed

Budapest, Hungary · Győr, Hungary · Kalocsa, Hungary

10 more locations

FAQ

Who is behind this study?

The study sponsor is Celon Pharma SA, a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including CPL500036 - low dose, CPL500036 - high dose and Placebo.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.